FINWIRES · TerminalLIVE
FINWIRES

Berenberg Keeps Hold Rating as Eni Ups FY26 Guidance After Q1 Miss

By

-- Eni (ENI.MI) logged a weaker-than-expected first quarter but guided for improved conditions for the full year, which Berenberg dissected in a note published Wednesday.

The Italian oil and gas company is rated hold with a price target of 22 euros.

The research firm noted that first-quarter adjusted EBIT was 11% lower than consensus, while the 20% jump in full-year operating cash flow expectations and a 90% surge in its share buyback guidance were supported by higher commodity prices.

However, expected lower results from Eni's downstream and global gas and LNG portfolio prompted analysts to cut their adjusted EPS projection for 2026 by 0.9%, and raise it by 1.1% and 1.5%, respectively, for 2027 and 2028.

"Eni has had an exceptional start to the year from an exploration standpoint ... Shareholder returns remain attractive, in our view, with a dividend yield of 4.4% and a buyback of around 4.2%, but after exceptional recent performance, we see better value elsewhere in the sector," analysts said.

Related Articles

Research

Research Alert: Abbvie: Solid Q1 Bolstered By Immunology And Neuroscience, Eps Guidance Raised

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AbbVie delivered strong Q1 2026 results with adjusted EPS of $2.65 (+7.7% Y/Y) slightly below the consensus of $2.67 due to $0.41 unfavorable impact from acquired IPR&D and milestones expense. Net revenues of $15.002B (+12.4% Y/Y) beat expectations by $280M, reflecting robust growth across key therapeutic areas. The successful transition from Humira to newer immunology assets continues to validate AbbVie's strategic positioning, with Skyrizi revenues of $4.483B (+30.9%) and Rinvoq revenues of $2.119B (+23.3%) substantially offsetting Humira's decline to $688M (-38.6%). The company raised its 2026 adjusted EPS guidance to $14.08-$14.28 from $13.96-$14.16, which includes the Q1 IPR&D impact. We believe the diversified growth platform demonstrates continued strength, with the immunology franchise generating $7.290B (+16.4%) and neuroscience portfolio delivering $2.875B (+26.0%). In our view, AbbVie's commitment to pipeline expansion through strategic investments positions the company well for sustained growth.

$ABBV
Research

Research Alert: Idex: High-growth Market Exposure Fuels Q1 Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IEX's Q1 results significantly exceeded expectations with operating EPS of $2.00 (up 14% Y/Y) vs. consensus of $1.77, representing a solid $0.23 beat, while organic sales growth accelerated to 5% from Q4's 1%. Orders hit a record $988M (up 10%) as demand broadened across the diversified portfolio. The Health & Science Tech segment was the primary growth driver, with 17% reported and 11% organic sales growth, plus 100 bps of adjusted EBITDA margin expansion to 26.6%, underpinned by AI-driven data center power solutions demand and semiconductor applications. Management raised full-year 2026 guidance, projecting organic sales growth of 3%-4% (up from 1%-2%) and adjusted EPS of $8.35-$8.55 (up from $8.15-$8.35). While gross margin declined 40 bps to 44.9% due to unfavorable mix, adjusted EBITDA margin expanded 50 bps to 26%, as 80/20 initiatives bear fruit. In our view, the upgraded outlook reflects an improved demand backdrop across IEX's diversified end markets.

$IEX
Research

SNB Capital Affirms Sabic at Neutral Rating, Cuts PT

SNB Capital on Wednesday reduced the price target for petrochemicals manufacturer Saudi Basic Industries (SASE:2010), d/b/a Sabic, to 64.50 Saudi riyals from 122.20 riyals, while maintaining its neutral rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SASE:2010